Recombinant Human GTPase NRas (NRAS) — Signal transducer in the Ras-MAPK signaling pathway that regulates cell proliferation and survival. Purity >85%.
| Product Sku | BCRECP-001276 |
| Product Description | Recombinant Human GTPase NRas (NRAS) Protein is expressed from E.coli with N-terminal 10xHis-GST-tagged and C-terminal Myc-tagged. It contains 1-186aa. [Accession | P01111]. |
| Uniprot No. | P01111 |
| Gene Names | NRAS |
| Purity | Greater than 85% as determined by SDS-PAGE. |
| Expression System | E.coli |
| Expression Region | 1-186aa |
| Species | Homo sapiens (Human) |
| Tag Info | N-terminal 10xHis-GST-tagged and C-terminal Myc-tagged |
| Molecular weight | 56.1kDa |
| Activity | Please contact us to obtain bioactivity data. |
| Buffer | If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose. |
| Storage | Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles. |
| Research Areas | Cancer |
Signal transducer in the Ras-MAPK signaling pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
Recombinant Human GTPase NRas (NRAS) — Signal transducer in the Ras-MAPK signaling pathway that regulates cell proliferation and survival. Purity >85%. Suitable for ELISA and Western Blot applications.
Recommended applications depend on the target, product format, and product-specific validation data. Refer to the product datasheet or Certificate of Analysis (CoA), or contact BioCrest Sci for application guidance.
Biological Activity: Please contact us to obtain bioactivity data.
Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shipping & Lead Time: Availability, shipping conditions, and estimated lead time are confirmed in the formal quotation or order confirmation based on the product format, destination, and order requirements.
Signal transducer in the Ras-MAPK signaling pathway that regulates cell proliferation and survival (PubMed:30712867). Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:30712867). Recognized by LZTR1 that mediates its ubiquitination by a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex (PubMed:40934300)
Cell membrane (Lipid-anchor); Golgi apparatus membrane (Lipid-anchor)
Leukemia, juvenile myelomonocytic (JMML) : An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. [The disease is caused by variants affecting the gene represented in this entry] | Noonan syndrome 6 (NS6) : A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. [The disease is caused by variants affecting the gene represented in this entry] | RAS-associated autoimmune leukoproliferative disorder (RALD) : A disorder of apoptosis, characterized by chronic accumulation of non-malignant lymphocytes, defective lymphocyte apoptosis, and an increased risk for the development of hematologic malignancies. [The disease is caused by variants affecting the gene represented in this entry] | Melanocytic nevus syndrome, congenital (CMNS) : A syndrome characterized by congenital pigmentary skin lesions which can occur at any site and can cover most of the body surface. These lesions may or may not be hairy. Congenital melanocytic nevi are associated with neuromelanosis (the presence of melanin-producing cells within the brain parenchyma or leptomeninges). Less commonly they are associated with malignant melanoma in childhood, both in the skin and the central nervous system. CMNS patients also tend to have a characteristic facial appearance, including wide or prominent forehead, periorbital fullness, small short nose with narrow nasal bridge, round face, full cheeks, prominent premaxilla, and everted lower lip. [The disease is caused by variants affecting the gene represented in this entry] | Melanosis, neurocutaneous (NCMS) : A rare congenital disease characterized by the presence of giant or multiple melanocytic nevi on the skin, foci of melanin-producing cells within the brain parenchyma, and infiltration of leptomeninges by abnormal melanin deposits. Neurologic abnormalities include seizures, hydrocephalus, arachnoid cysts, tumors, and syringomyelia. Some patients may develop malignant melanoma. [The disease is caused by variants affecting the gene represented in this entry] | Keratinocytic non-epidermolytic nevus (KNEN) : Epidermal nevi of the common, non-organoid and non-epidermolytic type are benign skin lesions and may vary in their extent from a single (usually linear) lesion to widespread and systematized involvement. They may be present at birth or develop early during childhood. [The disease is caused by variants affecting the gene represented in this entry] | Thyroid cancer, non-medullary, 2 (NMTC2) : A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms. [Disease susceptibility is associated with variants affecting the gene represented in this entry]
Interacts (active GTP-bound form preferentially) with RGS14 (By similarity). Interacts (active GTP-bound form) with RASSF7 (PubMed:21278800). Interacts (active GTP-bound form) with both SHOC2 and PP1c (all isoforms) to form a tertiary complex; SHOC2 and PP1c preferably bind M-Ras/MRAS, but they also bind K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS (PubMed:36175670, PubMed:35768504, PubMed:35831509, PubMed:35830882). Interacts (GDP-bound form) with LZTR1; this interaction mediates NRAS ubiquitination by BCR E3 ligase complex (PubMed:40934300)
Explore closely related product collections, technology platforms, and custom production resources.
Submit the Online Inquiry form with your required quantity and specifications, or email sales@biocrestsci.com. Available sizes, pricing, stock status, documentation, and estimated lead time are confirmed in the formal quotation.
Availability, dispatch timing, shipping conditions, and delivery estimates depend on the product format, destination, and order requirements. These details are confirmed in the formal quotation or order confirmation.
Follow the storage and handling instructions in the product-specific datasheet and Certificate of Analysis (CoA). Requirements may vary by product form and formulation; contact BioCrest Sci if product-specific guidance is needed.
Quality-control data such as identity, purity, endotoxin level, or biological activity are provided only when specified on this product page, the datasheet, or Certificate of Analysis (CoA). Biological activity is not implied unless explicitly stated.
